The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies, with maximum revenue generated from the BSI CALID segment. For 2026, Bruker anticipates flat to low single-digit organic revenue growth and significant improvement in non-GAAP operating margins.
Cyborg Score Rationale
Trailing twelve month revenue stands at $3.44 billion with a three-year revenue growth rate of 12.5%. However, operating margin has declined over the past five years, currently at 7.95%, and heavy reliance on academic and government research funding poses structural risks, especially amid major budget cuts.
Top Insights
Strong book-to-bill ratio exceeding 1.0 indicates robust order backlog
Increasing service, software, and consumables revenues enhance earnings resilience and support long-term profitability
Academic and government research funding reliance creates vulnerability to budget cuts in key markets
Recent acquisition of AST Revolution completed November 2025 signals continued M&A activity
Named Competitors
Thermo Fisher Scientific — Diversified life sciences and analytical instruments
Bio-Rad Laboratories — Life science research and clinical diagnostics
Revvity — Analytical instruments and life sciences services
GE HealthCare — Healthcare imaging and diagnostics
Recent Developments
(January 2026) Provided positive 2026 outlook with margin improvement guidance at J.P. Morgan Healthcare Conference
(November 2025) Completed acquisition of AST Revolution
(September 2025) Released Q3 2025 earnings with continued instrument order momentum
Open the full interactive Bruker Corporation report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.